Version June 2024
| Subtypes | Frequency | Genomic alterations | Predominant histopathology | Other features |
| GS | ~20% | CDH1 alteration RHOA alteration | Poorly cohesive | Younger patients Worst prognosis |
| CIN | ~50% | TP53 mutation ERBB2 amplification KRAS mutation | Intestinal | Male predominance High rate of nodal metastases |
| MSI | ~22% | CMIP MLH1 sequencing ARID1A mutation | Intestinal | Distal stomach Low rate of nodal metastases |
| EBV-positive | ~8% | CMIP PIK3 mutation ARID1A mutation PDL1/L2 amplification | Medullary (some intestinal) | Proximal stomach Low rate of nodal metastases |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
